Mononucleosis medical therapy

Jump to navigation Jump to search

Overview

Infectious mononucleosis is generally self-limiting and only symptomatic and/or supportive treatments are used. However, severe tonsillar enlargement may cause life-threatening airway obstruction and therefore, close monitoring of such high-risk patients is essential. Glucocorticoids may be indicated in such cases of severe airway obstruction. Acyclovir has been tried as they decrease oropharyngeal viral shedding. Recently, valacyclovir has shown to lower or eliminate the presence of the Epstein-Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.

Treatment

Supportive Therapy:

  • Infectious mononucleosis is generally self-limiting and only symptomatic and/or supportive treatments are used.[1]
  • Rest is recommended during the acute phase of the infection, but activity should be resumed once acute symptoms have resolved (~3 weeks).
  • Contact sports or heavy physical activity should be avoided for a minimum 6-8 weeks or until splenomegaly has resolved as determined by ultrasound scan, to abrogate the risk of splenic rupture which is a common complication among these patients.[1]

Pharmacotherapy:

  • There is little evidence to support the use of acyclovir, although it may reduce initial oropharyngeal viral shedding.[5] However, the antiviral drug valacyclovir has recently been shown to lower or eliminate the presence of the Epstein-Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.[6][7][8]
  • Antibiotics are not used as they are ineffective against viral infections. The antibiotics amoxicillin and ampicillin are contraindicated in the case of any coinciding bacterial infections during mononucleosis because their use can frequently precipitate a non-allergic rash.

References

  1. 1.0 1.1 Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, editors., eds. (2006). The Merck manual of diagnosis and therapy (18th ed. ed.). Whitehouse Station (NJ): Merck Research Laboratories. ISBN 0-911910-18-2.
  2. Candy B, Hotopf M. (2006). "Steroids for symptom control in infectious mononucleosis". Cochrane Database Sys Rev (4): CD004402. doi:10.1002/14651858.CD004402.pub2. PMID 16856045.
  3. 3.0 3.1 Antibiotic Expert Group. Therapeutic guidelines: Antibiotic. 13th ed. North Melbourne: Therapeutic Guidelines; 2006.
  4. "Infectious Mononucleosis". WebMD. Jan 24, 2006. Retrieved 2006-07-10.
  5. Torre D, Tambini R (1999). "Acyclovir for treatment of infectious mononucleosis: a meta-analysis". Scand. J. Infect. Dis. 31 (6): 543–7. PMID 10680982.
  6. Balfour HH, Hokanson KM, Schacherer RM; et al. (2007). "A virologic pilot study of valacyclovir in infectious mononucleosis". J. Clin. Virol. 39 (1): 16–21. doi:10.1016/j.jcv.2007.02.002. PMID 17369082.
  7. Simon; et al. (2003). "The Effect of Valacyclovir and Prednisolone in Reducing Symptoms of EBV Illness In Children: A Double-Blind, Placebo-Controlled Study". International Pediatrics. 18 (3): 164–169. Unknown parameter |month= ignored (help)
  8. Balfour HH, Hokanson KM, Schacherer RM; et al. (2007). "A virologic pilot study of valacyclovir in infectious mononucleosis". J. Clin. Virol. 39 (1): 16–21. doi:10.1016/j.jcv.2007.02.002. PMID 17369082.


Template:WikiDoc Sources